drugset / Trial / NCT00325494
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to establish the safest doses of an investigational drug called MORAb-009 in subjects with pancreatic cancer, mesothelioma, or certain types of ovarian or lung cancer. MORAb-009 is a monoclonal antibody that is directed to an antigen on the surface of these cancers.
Timeline
- Start
- 2006-05
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amatuximab | Monoclonal antibody | 12.5 mg/m2 | — |
| Subject | Amatuximab | Monoclonal antibody | 25 mg/m2 | — |
| Subject | Amatuximab | Monoclonal antibody | 50 mg/m2 | — |
| Subject | Amatuximab | Monoclonal antibody | 100 mg/m2 | — |
| Subject | Amatuximab | Monoclonal antibody | 200 mg/m2 | — |
| Subject | Amatuximab | Monoclonal antibody | 400 mg/m2 | — |